Back to today’s briefing

Story perspectives

NHS Approves £1.65M Gene Therapy for Sickle Cell Hope

2/3/2025

36 3

Summary

Story summary

The NHS has greenlit the revolutionary gene therapy Casgevy for sickle cell disease, bringing hope to approximately 50 patients each year. Priced at £1.65 million, this innovative treatment harnesses Crispr technology to boost fetal hemoglobin production, promising to change lives. While experts celebrate this milestone, they caution that not every patient may be eligible for this life-altering option.

1 of 1

Story summary

The NHS has greenlit the revolutionary gene therapy Casgevy for sickle cell disease, bringing hope to approximately 50 patients each year. Priced at £1.65 million, this innovative treatment harnesses Crispr technology to boost fetal hemoglobin production, promising to change lives. While experts celebrate this milestone, they caution that not every patient may be eligible for this life-altering option.